Updated Jul 16, 2026
CAGNONI PABLO J has filed 4 SEC Form 4 filings across 1 company in the last 90 days — selling. Lifetime open-market sales: $5.44M.

Pablo J. Cagnoni is the President of Incyte Corporation, a biopharmaceutical company focused on the development of innovative therapies for cancer and other serious diseases. He has played a significant role in advancing the company's drug development pipeline, including its leading drug Jakafi.
| Role | President, Global Head of R&D |
|---|---|
| Notability | 50/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-06-03 | INCY | INCYTE CORP | F — Tax withholding / forfeiture | 25.5K | $95.59 | $2.43M |
| 2026-05-20 | INCY | INCYTE CORP | A — Grant or award | 31.5K | $0.00 | |
| 2026-04-21 | INCY | INCYTE CORP | S — Open-market sale | 18.7K | $96.50 | $1.80M |
| 2026-04-21 | INCY | INCYTE CORP | M — Option exercise | 12.6K | $71.93 | $906K |
| 2026-04-21 | INCY | INCYTE CORP | M — Option exercise | 6.1K | $64.25 | $390K |
| 2026-04-17 | INCY | INCYTE CORP | A — Grant or award | 27.9K | $0.00 | |
| 2026-03-19 | INCY | INCYTE CORP | S — Open-market sale | 18.7K | $94.24 | $1.76M |
| 2026-03-19 | INCY | INCYTE CORP | M — Option exercise | 11.5K | $64.25 | $739K |
| 2026-03-19 | INCY | INCYTE CORP | M — Option exercise | 7.2K | $61.18 | $438K |
| 2026-02-23 | INCY | INCYTE CORP | S — Open-market sale | 18.7K | $100.91 | $1.88M |
| 2026-02-23 | INCY | INCYTE CORP | M — Option exercise | 5.6K | $61.18 | $341K |
| 2026-02-23 | INCY | INCYTE CORP | M — Option exercise | 13.1K | $61.76 | $809K |
| 2025-07-14 | INCY | INCYTE CORP | A — Grant or award | 17.5K | $0.00 | |
| 2025-07-14 | INCY | INCYTE CORP | F — Tax withholding / forfeiture | 2.6K | $68.25 | $179K |
| 2025-07-14 | INCY | INCYTE CORP | F — Tax withholding / forfeiture | 1.3K | $69.98 | $90K |
Pablo J. Cagnoni is the President of Incyte Corporation, a biopharmaceutical company focused on the development of innovative therapies for cancer and other serious diseases. He has played a significant role in advancing the company's drug development pipeline, including its leading drug Jakafi.…
4 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 0 open-market purchases () and 3 open-market sales ($5.44M) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live CAGNONI PABLO J profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.